Literature DB >> 33734385

Nocturnal hypoxemia severity influences the effect of CPAP therapy on renal renin-angiotensin-aldosterone system activity in humans with obstructive sleep apnea.

David D M Nicholl1, Patrick J Hanly2,3,4, Ann A Zalucky5, George B Handley6, Darlene Y Sola2, Sofia B Ahmed2,7,8.   

Abstract

STUDY
OBJECTIVES: Nocturnal hypoxemia (NH) in obstructive sleep apnea (OSA) is associated with renal renin-angiotensin-aldosterone system (RAAS) up-regulation and loss of kidney function. Continuous positive airway pressure (CPAP) therapy is associated with RAAS down-regulation, though the impact of NH severity remains unknown. We sought to determine whether NH severity alters the effect of CPAP on renal hemodynamics and RAAS activity in humans.
METHODS: Thirty sodium-replete, otherwise healthy, OSA participants (oxygen desaturation index ≥ 15 h-1) with NH (SpO2 < 90% ≥ 12%/night) were studied pre- and post-CPAP (>4 h/night∙4 weeks). NH severity was characterized as moderate (mean SpO2[MSpO2] ≥ 90%; N = 15) or severe (MSpO2 < 90%; N = 15). Glomerular filtration rate (GFR), renal plasma flow (RPF), and filtration fraction (FF) were measured at baseline and in response to angiotensin-II (3 ng/kg/min∙30 min, 6 ng/kg/min∙30 min), a marker of RAAS activity.
RESULTS: Pre-CPAP, baseline renal hemodynamics did not differ by NH severity. Pre-CPAP, severe NH participants demonstrated blunted GFR (Δ30 min, -9 ± 4 vs 1 ± 3 mL/min, p = 0.021; Δ60 min, -5 ± 5 vs 8 ± 5 mL/min, p = 0.017) and RPF (Δ30 min, -165 ± 13 vs -93 ± 19 mL/min, p = 0.003; Δ60 min, -208 ± 18 vs -112 ± 22 mL/min, p = 0.001; moderate vs severe) responses to angiotensin-II. Post-CPAP, severe NH participants demonstrated maintained GFR (112 ± 5 vs 108 ± 3 mL/min, p = 0.9), increased RPF (664 ± 35 vs 745 ± 34 mL/min, p = 0.009), reduced FF (17.6 ± 1.4 vs 14.9 ± 0.6%, p = 0.009), and augmented RPF responses to Angiotensin-II (Δ30 min, -93 ± 19 vs -138 ± 16 mL/min, p = 0.009; Δ60 min, -112 ± 22 vs -175 ± 20 mL/min, p = 0.001; pre- vs post-CPAP), while moderate participants were unchanged.
CONCLUSIONS: Correction of severe, but not moderate, NH with CPAP therapy was associated with improved renal hemodynamics and decreased renal RAAS activity in humans with OSA. © Sleep Research Society 2020. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please e-mail journals.permissions@oup.com.

Entities:  

Keywords:  CPAP; nocturnal hypoxemia; obstructive sleep apnea; renal hemodynamics; renin–angiotensin–aldosterone system

Year:  2021        PMID: 33734385     DOI: 10.1093/sleep/zsaa228

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  4 in total

1.  Risk of chronic kidney disease in patients with obstructive sleep apnea.

Authors:  Andrew E Beaudin; Jill K Raneri; Sofia B Ahmed; A J Marcus Hirsch Allen; Andrhea Nocon; Teresa Gomes; Simon Gakwaya; Fréderic Series; John Kimoff; Robert P Skomro; Najib T Ayas; Patrick J Hanly
Journal:  Sleep       Date:  2022-02-14       Impact factor: 5.849

2.  Association of insomnia and short sleep duration, alone or with comorbid obstructive sleep apnea, and the risk of chronic kidney disease.

Authors:  Andrew E Beaudin; Jill K Raneri; Sofia Ahmed; A J Hirsch Allen; Andrhea Nocon; Teresa Gomes; Simon Gakwaya; Frédéric Sériès; John R Kimoff; Robert Skomro; Najib Ayas; Patrick J Hanly
Journal:  Sleep       Date:  2022-07-11       Impact factor: 6.313

Review 3.  The Role of Aldosterone in OSA and OSA-Related Hypertension.

Authors:  Yi Wang; Chuan Xiang Li; Ying Ni Lin; Li Yue Zhang; Shi Qi Li; Liu Zhang; Ya Ru Yan; Fang Ying Lu; Ning Li; Qing Yun Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-12       Impact factor: 5.555

Review 4.  Cardiac consequences of intermittent hypoxia: a matter of dose? A systematic review and meta-analysis in rodents.

Authors:  Elise Belaidi; Charles Khouri; Olfa Harki; Sébastien Baillieul; Gilles Faury; Anne Briançon-Marjollet; Jean-Louis Pépin; Claire Arnaud
Journal:  Eur Respir Rev       Date:  2022-04-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.